CSF1R and Patent ductus arteriosus: Unfortunately, the CSF1R-blocking monoclonal antibody cabiralizumab combined with nivolumab and chemotherapy in advanced PDA did not improve progression-free survival in a phase II clinical trial (ClinicalTrials.gov NCT03336216).